Andros Pharmaceuticals Co (ROCO:6917) Short-Term Capital Lease Obligation : NT$5.17 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Short-Term Capital Lease Obligation?

Andros Pharmaceuticals Co's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$5.17 Mil.

Andros Pharmaceuticals Co's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 (NT$5.10 Mil) to Jun. 2024 (NT$5.13 Mil) and increased from Jun. 2024 (NT$5.13 Mil) to Dec. 2024 (NT$5.17 Mil).

Andros Pharmaceuticals Co's annual Short-Term Capital Lease Obligation increased from Dec. 2022 (NT$4.85 Mil) to Dec. 2023 (NT$5.10 Mil) and increased from Dec. 2023 (NT$5.10 Mil) to Dec. 2024 (NT$5.17 Mil).

Andros Pharmaceuticals Co Short-Term Capital Lease Obligation Historical Data

The historical data trend for Andros Pharmaceuticals Co's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Short-Term Capital Lease Obligation Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

4.53

4.68

4.85

5.10

5.17

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial					4.85	5.06	5.10	5.13	5.17

Andros Pharmaceuticals Co Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Andros Pharmaceuticals Co Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co Headlines

No Headlines